Navigation Links
Bellicum Pharmaceuticals Raises $34.4 Million in a Series B Financing
Date:1/7/2014

HOUSTON, Jan. 7, 2014 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. announced today that it has completed a second and final closing of its Series B financing, securing an additional $14.7 million and bringing the total raised in the round to $34.4 million. Current investors provided the additional funding, including AVG Ventures and Remeditex Ventures.

The funding will be used to expand clinical development of Bellicum's lead cellular immunotherapy product candidates.

"Bellicum is well positioned within the highly promising field of cellular immunotherapy with a technology that provides control over cells after they have been administered to the patient," said Bellicum CEO Tom Farrell. "This funding will be used to advance our two clinical programs in leukemia/lymphoma and prostate cancer, and launch studies in additional indications where there is urgent need for safer and more effective cell therapies."

Bellicum's two lead clinical development programs utilize the Company's unique ability to control cell therapies once inside the body. BPX-501 T cells contain the Company's CaspaCIDe™ gene "safety switch," enabling physicians to eliminate transplanted cells in the event they become harmful to the patient. The product is being evaluated in a Phase I/II study to reduce or eliminate Graft versus Host Disease in cancer patients undergoing hematopoietic stem cell transplant.

BPX-201 dendritic cells contain the Company's DeCIDe® gene "on switch," which enables physicians to strategically target immune activation for a more potent anti-tumor effect. It is being evaluated in a Phase I clinical trial in patients with metastatic castrate-resistant prostate cancer.

About Bellicum Pharmaceuticals

Bellicum is dedicated to developing safer and more effective cell therapies to treat cancers and other serious, life-threatening diseases. The Company's cell therapies are engineered with a gene "switch" that enables physicians to activate or eliminate cells once inside the body to improve safety and efficacy. Bellicum is advancing clinical programs in cellular transplants to reduce or eliminate Graft versus Host Disease, and in prostate cancer with a potentially more potent immunotherapy. For more information please visit www.bellicum.com


'/>"/>
SOURCE Bellicum Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Jazz Pharmaceuticals to Present at J.P. Morgan Healthcare Conference on January 13
2. Avanir Pharmaceuticals to Present at J.P. Morgan 32nd Annual Healthcare Conference
3. ANI Pharmaceuticals Enters Development Agreement for Generic Drug Product with Sterling Pharmaceutical Services
4. Arena Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference
5. Isis Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference
6. Inovio Pharmaceuticals to Present at Biotech Showcase 2014 Investor Conference
7. Global Radiopharmaceuticals Market Report 2013 - 2018
8. Pre-Market Update: MGT Capital Investments, National American University Holdings and Actinium Pharmaceuticals
9. ANI Pharmaceuticals Acquires 31 Generic Drug Products from Teva Pharmaceuticals
10. New Appointments, and Share Price Movements - Research Report on Humana, Illumina, Edwards Lifesciences, Aegerion Pharmaceuticals, and CytRx
11. Taiwan Spends a High Percentage of its Healthcare Budget on Pharmaceuticals, but Second Generation Healthcare Reform is Transforming the Market Landscape
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... COTTAGE, New York , January 13, 2017 ... and rising prevalence of AIDS will collectively contribute to the ...  is expected to reach a value of US$ 551.0 Mn ... will remain the most lucrative markets for western ... to lead the market globally. ...
(Date:1/13/2017)... Jan. 13, 2017 Wichita Laser Clinic ... laser treatments to Wichita, Kansas ... advanced treatments for skin rejuvenation, getting rid of unwanted ... and vascular lesions. "Since being in the ... Wichita for laser tattoo removal ...
(Date:1/13/2017)... -- The 2016 election resulted in a big ... in favor of legalizing cannabis for recreational use, including ... U.S. In addition, the state of Colorado ... sales. The ArcView Group has published an updated research report ... in the U.S. last year reached $6.7 billion, a growth of ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... Atlanta-based incentive company ... innovator in the wheelchair accessibility industry, BraunAbility . Incentive Solutions will provide ... wheelchair accessible vehicles. With this new incentive plan, BraunAbility plans to continue their ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... teacher, http://www.ageofautism.com/legal , Sharon Kleyne, America’s leading water educator, researcher and ... nationally syndicated radio program, The Sharon Kleyne Hour Power of Water, Global Climate ...
(Date:1/16/2017)... ... 16, 2017 , ... In 1985, the International Association of ... to an international multidisciplinary group of healthcare treatment providers and helping professions who ... its mission at the grassroots level, iaedp launched MemberSHARE, an online peer community ...
(Date:1/16/2017)... ... ... San Francisco dentist, Dr. Ben Amini , the founder at CitiDent, ... capable of taking digital impressions of teeth and gums. Conventional bite impressions have lagged ... , in terms of speed, efficiency and patient comfort. Increasingly, digital impressions are being ...
(Date:1/16/2017)... ... January 16, 2017 , ... NexTec Group has been selected ... 100 organizations honored for their accomplishments in the field of midmarket financial software. , ... and recognition, and innovation. Selection is not based on revenue and those firms chosen ...
Breaking Medicine News(10 mins):